Barclays Maintains Overweight on Sotera Health, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Overweight rating on Sotera Health (NASDAQ:SHC) but lowered the price target from $20 to $15.
November 02, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Overweight rating on Sotera Health but lowered the price target from $20 to $15.
The lowering of the price target by Barclays from $20 to $15 indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that Barclays still sees potential in the company's stock, which may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100